Highest-materiality recent filing
Tevogen Bio receives Nasdaq deficiency notices for market value requirements
Nasdaq notified Tevogen on Apr 16, 2026 it fails $50M minimum market value for listed securities (MVLS).
Tevogen Bio regains Nasdaq minimum bid price compliance after reverse split
Received Nasdaq notice on March 20, 2026 confirming compliance with Listing Rule 5450(a)(1).
Reverse stock split ratio 1-for-50; effective 12:01 a.m. March 6, 2026.
Tevogen Bio shareholders approve 100M share increase and reverse stock split authorization
Shareholders approved amending 2024 Omnibus Incentive Plan to add 100,000,000 shares, effective Feb 19, 2026.
Tevogen Bio board to evaluate potential one-time special cash dividend after unspecified milestones
Board intends to evaluate a special cash dividend contingent on future financial milestones (revenue, earnings targets).
Tevogen Bio gets Nasdaq deficiency notice; must regain $1.00 bid by March 2026
Received letter on September 23, 2025 from Nasdaq Staff for non-compliance with $1.00 minimum bid price rule.
Tevogen Bio grants 8M restricted shares to CEO; total outstanding 193.7M shares
Board approved restricted stock awards on June 27, 2025, including 8M shares to CEO Dr. Ryan Saadi.
Tevogen Bio enters $50M at-the-market equity sales agreement with A.G.P.
Sales agreement allows issuance and sale of up to $50M of common stock from time to time.
CEO Ryan Saadi contributes $500,000 to Tevogen Bio for new HQ costs
Founder and CEO Ryan Saadi contributed $500,000 cash to Tevogen Bio on June 30, 2025.
Stockholders elect Feike and Patton as Class I directors; ratify KPMG as auditor.
Jeffrey Feike received 150,304,146 votes for and 652,203 against; Dr. Curtis Patton: 150,313,660 for, 647,811 against.
Tevogen Bio doubles HQ leased space to 13,242 RSF; lease extended to Feb 2033
Lease amendment doubles space from 6,708 to 13,242 rentable square feet on Building's 2nd floor.
Tevogen Bio amends Bylaws to modify director resignation procedure for majority vote failures
Board amended Bylaws on April 21, 2025 to alter process for director resignations when director fails to receive majority vote in uncontested election.
Tevogen Bio inks related-party facility deal with CD8 for cell therapy production
Agreement with CD8 Technology Services (associated with >5% holder Dr. Manmohan Patel) for turn-key GMP cell therapy production facility.
Tevogen Bio receives $2M grant from KRHP LLC; up to $10M non-dilutive funding
Initial $2M grant from KRHP LLC; additional $8M contingent on KRHP's review of activities.
Tevogen Bio raises $6M via Series C Preferred Stock; two closings Aug 30 & Sept 16
Investor to purchase 600 shares of Series C Preferred Stock for $6.0 million aggregate.
Tevogen Bio raises $6M via Series C Preferred; director Suren Ajjarapu resigns
Sold 600 shares of Series C Preferred at $10,000 each for $6.0M aggregate to The Patel Family, LLP.
Tevogen Bio receives Nasdaq bid price deficiency notice, repurchases Series B Preferred Stock
Received Nasdaq letter on June 14, 2024, for non-compliance with $1.00 minimum bid price rule for 35 consecutive business days.
Tevogen Bio secures $36M unsecured credit line from 5% owner Patel Family; equity-linked terms
Loan agreement with The Patel Family LLP (affiliate of 5% holder Manmohan Patel) for up to $36M unsecured facility.
Tevogen Bio Inc reports 2023 net loss of $60.5M; cash only $1.05M, going concern raised
Net loss of $60.5M in 2023 ($2.44/share) vs $22.0M in 2022; no revenue.
Tevogen Bio enters $36M line of credit with Patel Family; also grants PIPE option for $14M+
Line of credit up to $36M, draws limited to $1M per month; interest lower of SOFR+2% or 7%.
Tevogen Bio Holdings appoints KPMG as auditor, dismisses Marcum
Audit committee appointed KPMG as independent auditor for FY2024, effective immediately.
Tevogen Bio's audited FY2023 shows $60.5M net loss, going concern doubt
Net loss of $60.5M in 2023 vs $22.0M in 2022; accumulated deficit $99.7M.
Expects to report $94.9M liability elimination from conversion of promissory notes into common stock.
On August 20, 2024, Suren Ajjarapu gave notice of his resignation from service as a director of the Company, effective August 21, 2024.
Max materiality 0.85 · Median 0.60 · Most common event other_material